In vitro antimicrobial activity of a commercial ear antiseptic containing chlorhexidine and Tris-EDTA.
Minimum bactericidal concentrations (MBCs) of a commercial ear antiseptic containing chlorhexidine 0.15% and Tris-EDTA (Otodine) were determined by broth microdilution for 150 isolates representing the most common pathogens associated with canine otitis. The microorganisms were classified into three groups according to their levels of susceptibility. The most susceptible group included Staphylococcus pseudintermedius, Malassezia pachydermatis, Streptococcus canis and Corynebacterium auriscanis, which were generally killed by 1 : 64 dilution of the antiseptic product (MBC = 23/0.8 microg/mL of chlorhexidine/Tris-EDTA). The most resistant organism was Proteus mirabilis, which survived up to 1 : 8 dilution of the product (MBC = 375/12 microg/mL). Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus displayed intermediate MBCs ranging between 188/6 and 47/1.5 microg/mL. Interestingly, S. pseudintermedius was more susceptible than S. aureus, and no significant difference was observed between meticillin-resistant and meticillin-susceptible isolates within each species, indicating that antiseptic use is unlikely to co-select for meticillin resistance. Although the concentrations required for killing (MBCs) varied considerably with microorganism type, the combination of chlorhexidine 0.15% and Tris-EDTA was active against all the pathogens most commonly involved in canine otitis.
Guardabassi
Luca
L
Department of Veterinary Disease Biology, Faculty of Life Sciences, University of Copenhagen, 1870 Frederiksberg C, Denmark.
Ghibaudo
Giovanni
G
Damborg
Peter
P
D000818:Animals; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002710:Chlorhexidine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy* / Q000382:microbiology; D004285:Dogs; D004492:Edetic Acid / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D010031:Otitis / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D011512:Proteus Infections / Q000188:drug therapy / Q000662:veterinary; D011513:Proteus mirabilis / Q000187:drug effects; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000662:veterinary; D013207:Staphylococcal Skin Infections / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary; D013210:Staphylococcus / Q000187:drug effects
D000891:Anti-Infective Agents, Local; D004492:Edetic Acid; D002710:Chlorhexidine